[
    {
        "id": "article-17954_14",
        "title": "Atomoxetine -- Adverse Effects -- Adverse Drug Reactions (1% to 10%)",
        "content": "Palpitations (3%), cold extremities (1% to 3%), prolonged QTc interval on ECG, increased diastolic blood pressure (5% to 9%), greater than or equal to 15 mmHg), systolic hypertension (4% to 5%), syncope (less than or equal to 3%), orthostatic hypotension (less than or equal to\u00a02%), tachycardia (less than or equal to\u00a02%) [15] Fatigue (6% to 10%), dizziness (5% to 8%), depression (4% to 7%), disturbed sleep (3% to 7%), irritability (5% to 6%), jitteriness (2% to 5%), abnormal dreams (4%), chills (3%), paresthesia (adults 3%; postmarketing observation in children), anxiety (greater than or equal to 2%), hostility (children and adolescents 2%), emotional lability (1% to 2%), agitation, restlessness, seizures [16]",
        "contents": "Atomoxetine -- Adverse Effects -- Adverse Drug Reactions (1% to 10%). Palpitations (3%), cold extremities (1% to 3%), prolonged QTc interval on ECG, increased diastolic blood pressure (5% to 9%), greater than or equal to 15 mmHg), systolic hypertension (4% to 5%), syncope (less than or equal to 3%), orthostatic hypotension (less than or equal to\u00a02%), tachycardia (less than or equal to\u00a02%) [15] Fatigue (6% to 10%), dizziness (5% to 8%), depression (4% to 7%), disturbed sleep (3% to 7%), irritability (5% to 6%), jitteriness (2% to 5%), abnormal dreams (4%), chills (3%), paresthesia (adults 3%; postmarketing observation in children), anxiety (greater than or equal to 2%), hostility (children and adolescents 2%), emotional lability (1% to 2%), agitation, restlessness, seizures [16]"
    },
    {
        "id": "First_Aid_Step2_1002",
        "title": "First_Aid_Step2",
        "content": "SSRIs Fluoxetine, sertraline, paroxetine, citalopram, f uvoxamine Depression and anxiety. Sexual side effects, GI distress, agitation, insomnia, tremor, diarrhea. Serotonin syndrome (fever, myoclonus, mental status changes, cardiovascular collapse) can occur if SSRIs are used with MAOIs. Paroxetine can cause pulmonary hypertension in the fetus. Atypicals Bupropion, venlafaxine, mirtazapine, trazodone Depression, anxiety, and chronic pain. Bupropion: \u2193 seizure threshold; minimal sexual side effects. Contraindicated in patients with eating disorders as well as in seizure patients. Venlafaxine: Diastolic hypertension. Mirtazapine: Weight gain, sedation. Trazodone: Highly sedating; priapism. Nortriptyline, desipramine, amitriptyline, imipramine Depression, anxiety disorder, chronic pain, migraine headaches, enuresis (imipramine). Lethal with overdose owing to cardiac conduction arrhythmias (e.g., long QRS). Monitor in the ICU for 3\u20134 days following an OD. Anticholinergic effects (dry",
        "contents": "First_Aid_Step2. SSRIs Fluoxetine, sertraline, paroxetine, citalopram, f uvoxamine Depression and anxiety. Sexual side effects, GI distress, agitation, insomnia, tremor, diarrhea. Serotonin syndrome (fever, myoclonus, mental status changes, cardiovascular collapse) can occur if SSRIs are used with MAOIs. Paroxetine can cause pulmonary hypertension in the fetus. Atypicals Bupropion, venlafaxine, mirtazapine, trazodone Depression, anxiety, and chronic pain. Bupropion: \u2193 seizure threshold; minimal sexual side effects. Contraindicated in patients with eating disorders as well as in seizure patients. Venlafaxine: Diastolic hypertension. Mirtazapine: Weight gain, sedation. Trazodone: Highly sedating; priapism. Nortriptyline, desipramine, amitriptyline, imipramine Depression, anxiety disorder, chronic pain, migraine headaches, enuresis (imipramine). Lethal with overdose owing to cardiac conduction arrhythmias (e.g., long QRS). Monitor in the ICU for 3\u20134 days following an OD. Anticholinergic effects (dry"
    },
    {
        "id": "InternalMed_Harrison_32158",
        "title": "InternalMed_Harrison",
        "content": "Oral or parenteral anticholinergic agent such as benztropine or diphenhydramine High-dose IV pyridoxine (vitamin B6) for agitation, confusion, coma, and seizures; diazepam or barbiturates for seizures Whole-bowel irrigation for large ingestions; IV hydration; hemodialysis for coma, seizures, encephalopathy or neuromuscular dysfunction (severe, progressive, or persistent), peak lithium level >4 meq/L following acute overdose Physiologic Condition, Causes Examples Mechanism of Action Clinical Features Specific Treatments Serotonin syndrome Amphetamines, cocaine, dextromethorphan, meperidine, MAO inhibitors, selective serotonin (5-HT) reuptake inhibitors, tricyclic antidepressants, tramadol, triptans, tryptophan",
        "contents": "InternalMed_Harrison. Oral or parenteral anticholinergic agent such as benztropine or diphenhydramine High-dose IV pyridoxine (vitamin B6) for agitation, confusion, coma, and seizures; diazepam or barbiturates for seizures Whole-bowel irrigation for large ingestions; IV hydration; hemodialysis for coma, seizures, encephalopathy or neuromuscular dysfunction (severe, progressive, or persistent), peak lithium level >4 meq/L following acute overdose Physiologic Condition, Causes Examples Mechanism of Action Clinical Features Specific Treatments Serotonin syndrome Amphetamines, cocaine, dextromethorphan, meperidine, MAO inhibitors, selective serotonin (5-HT) reuptake inhibitors, tricyclic antidepressants, tramadol, triptans, tryptophan"
    },
    {
        "id": "article-17149_7",
        "title": "Acute Chest Syndrome -- Epidemiology",
        "content": "Acute chest syndrome\u00a0is the most prevalent\u00a0acute pulmonary disorder in individuals\u00a0with sickle cell disease. [5] Approximately 50%\u00a0of patients with sickle cell disease will experience\u00a0more than 1\u00a0episode of acute chest syndrome. The peak incidence of acute chest syndrome is observed in pediatric patients between 2 and\u00a04 years old. Among adults, 78% of acute chest syndrome episodes are secondary to vaso-occlusive pain episodes. Acute chest syndrome is the most common cause of death in\u00a0individuals with sickle cell disease, accounting for nearly 25% of all deaths. The mortality rates associated with acute chest syndrome are 4.3% in adults and 1.1% in children.",
        "contents": "Acute Chest Syndrome -- Epidemiology. Acute chest syndrome\u00a0is the most prevalent\u00a0acute pulmonary disorder in individuals\u00a0with sickle cell disease. [5] Approximately 50%\u00a0of patients with sickle cell disease will experience\u00a0more than 1\u00a0episode of acute chest syndrome. The peak incidence of acute chest syndrome is observed in pediatric patients between 2 and\u00a04 years old. Among adults, 78% of acute chest syndrome episodes are secondary to vaso-occlusive pain episodes. Acute chest syndrome is the most common cause of death in\u00a0individuals with sickle cell disease, accounting for nearly 25% of all deaths. The mortality rates associated with acute chest syndrome are 4.3% in adults and 1.1% in children."
    },
    {
        "id": "article-24262_26",
        "title": "Lidocaine -- Administration -- Adult Dosage",
        "content": "Doses used for infiltrative or regional anesthesia depend on the specific block. When lidocaine is used to obtund airway reflexes, the dose is 1 to 2 mg/kg, given 2 to 5 minutes before intubation. For cardiac dysrhythmias, the initial dose is 1 to 1.5 mg/kg given intravenously, optionally followed with an infusion. [5] As an adjuvant intravenous treatment for acute pain, a 2020 consensus statement suggested a loading dose of no more than 1.5mg/kg over 10 minutes, followed by an infusion of no more than 1.5mg/kg/h for no longer than 24 hours (with\u00a0close monitoring for clinical response and signs of toxicity). [17] The American Society of Anesthesiologists panel noted the absence of definitive evidence regarding the optimal dosing of lidocaine. However, based on clinical experience, the ASA recommends administering an induction dose of 1.5 mg/kg, followed by an intraoperative infusion of 2 mg/kg/h for patients undergoing open and laparoscopic abdominal surgeries. [9] For awake intubation, effective topical application must be ensured. The maximum dose of lidocaine should not exceed 9 mg/kg of lean body weight. To minimize the risk of laryngospasm, clinicians should consider nebulized lidocaine and lower concentrations. [10]",
        "contents": "Lidocaine -- Administration -- Adult Dosage. Doses used for infiltrative or regional anesthesia depend on the specific block. When lidocaine is used to obtund airway reflexes, the dose is 1 to 2 mg/kg, given 2 to 5 minutes before intubation. For cardiac dysrhythmias, the initial dose is 1 to 1.5 mg/kg given intravenously, optionally followed with an infusion. [5] As an adjuvant intravenous treatment for acute pain, a 2020 consensus statement suggested a loading dose of no more than 1.5mg/kg over 10 minutes, followed by an infusion of no more than 1.5mg/kg/h for no longer than 24 hours (with\u00a0close monitoring for clinical response and signs of toxicity). [17] The American Society of Anesthesiologists panel noted the absence of definitive evidence regarding the optimal dosing of lidocaine. However, based on clinical experience, the ASA recommends administering an induction dose of 1.5 mg/kg, followed by an intraoperative infusion of 2 mg/kg/h for patients undergoing open and laparoscopic abdominal surgeries. [9] For awake intubation, effective topical application must be ensured. The maximum dose of lidocaine should not exceed 9 mg/kg of lean body weight. To minimize the risk of laryngospasm, clinicians should consider nebulized lidocaine and lower concentrations. [10]"
    },
    {
        "id": "Pharmacology_Katzung_5231",
        "title": "Pharmacology_Katzung",
        "content": "Peripheral neuropathy is observed in 10\u201320% of patients given dosages greater than 5 mg/kg/d, but it is infrequently seen with the standard 300-mg adult dose. Peripheral neuropathy is more likely to occur in slow acetylators and patients with predisposing conditions such as malnutrition, alcoholism, diabetes, AIDS, and uremia. Neuropathy is due to a relative pyridoxine deficiency. Isoniazid promotes excretion of pyridoxine, and this toxicity is readily reversed by administration of pyridoxine in a dosage as low as 10 mg/d. Central nervous system toxicity, which is less common, includes memory loss, psychosis, ataxia, and seizures. These effects may also respond to pyridoxine. Miscellaneous other reactions include hematologic abnormalities, provocation of pyridoxine deficiency anemia, tinnitus, and gastrointestinal discomfort.",
        "contents": "Pharmacology_Katzung. Peripheral neuropathy is observed in 10\u201320% of patients given dosages greater than 5 mg/kg/d, but it is infrequently seen with the standard 300-mg adult dose. Peripheral neuropathy is more likely to occur in slow acetylators and patients with predisposing conditions such as malnutrition, alcoholism, diabetes, AIDS, and uremia. Neuropathy is due to a relative pyridoxine deficiency. Isoniazid promotes excretion of pyridoxine, and this toxicity is readily reversed by administration of pyridoxine in a dosage as low as 10 mg/d. Central nervous system toxicity, which is less common, includes memory loss, psychosis, ataxia, and seizures. These effects may also respond to pyridoxine. Miscellaneous other reactions include hematologic abnormalities, provocation of pyridoxine deficiency anemia, tinnitus, and gastrointestinal discomfort."
    },
    {
        "id": "article-18838_14",
        "title": "Carbamazepine -- Toxicity",
        "content": "In adults, doses of carbamazepine exceeding 24 grams have correlated with fatal outcomes. Acute toxicity appears after 1 to 3 hours of intake and presents with neuromuscular disturbances. Patients have impaired consciousness leading to coma, tremor, restlessness, athetoid movements, psychomotor disturbances, dizziness, drowsiness, mydriasis, and nystagmus. Initially, patients experience hyperreflexia, but during intoxication, they progress into a state of hyporeflexia. Cardiac, vascular signs are generally mild with low toxicity, but with doses higher than 60 grams, severe cardiac dysfunction can occur.\u00a0In cases of acute toxicity, respiratory depression, ECG abnormalities, tachycardia, shock, and urinary retention require monitoring and management to avoid end-organ damage. Treatment of an overdose focuses on eliminating the drug by inducing vomiting, gastric lavage, activated charcoal, and forced diuresis. Gastric lavage is indicated even after 4 hours of indigestion. [21] Seizures caused by carbamazepine poisoning should receive treatment with benzodiazepines such as diazepam.",
        "contents": "Carbamazepine -- Toxicity. In adults, doses of carbamazepine exceeding 24 grams have correlated with fatal outcomes. Acute toxicity appears after 1 to 3 hours of intake and presents with neuromuscular disturbances. Patients have impaired consciousness leading to coma, tremor, restlessness, athetoid movements, psychomotor disturbances, dizziness, drowsiness, mydriasis, and nystagmus. Initially, patients experience hyperreflexia, but during intoxication, they progress into a state of hyporeflexia. Cardiac, vascular signs are generally mild with low toxicity, but with doses higher than 60 grams, severe cardiac dysfunction can occur.\u00a0In cases of acute toxicity, respiratory depression, ECG abnormalities, tachycardia, shock, and urinary retention require monitoring and management to avoid end-organ damage. Treatment of an overdose focuses on eliminating the drug by inducing vomiting, gastric lavage, activated charcoal, and forced diuresis. Gastric lavage is indicated even after 4 hours of indigestion. [21] Seizures caused by carbamazepine poisoning should receive treatment with benzodiazepines such as diazepam."
    },
    {
        "id": "InternalMed_Harrison_31704",
        "title": "InternalMed_Harrison",
        "content": "SSRIs such as fluoxetine, sertraline, paroxetine, citalopram, and escitalopram cause a lower frequency of anticholinergic, sedating, and cardiovascular side effects but a possibly greater incidence of gastrointestinal complaints, sleep impairment, and sexual dysfunction than do TCAs. Akathisia, involving an inner sense of restlessness and anxiety in addition to increased motor activity, may also be more common, particularly during the first week of treatment. One concern is the risk of \u201cserotonin syndrome,\u201d which is thought to result from hyperstimulation of brainstem 5-HT1A receptors and characterized by myoclonus, agitation, abdominal cramping, hyperpyrexia, hypertension, and potentially death. Serotonergic agonists taken in combination should be monitored closely for this reason. Considerations such as half-life, compliance, toxicity, and drug-drug interactions may guide the choice of a particular SSRI. Fluoxetine and its principal active metabolite, norfluoxetine, for example,",
        "contents": "InternalMed_Harrison. SSRIs such as fluoxetine, sertraline, paroxetine, citalopram, and escitalopram cause a lower frequency of anticholinergic, sedating, and cardiovascular side effects but a possibly greater incidence of gastrointestinal complaints, sleep impairment, and sexual dysfunction than do TCAs. Akathisia, involving an inner sense of restlessness and anxiety in addition to increased motor activity, may also be more common, particularly during the first week of treatment. One concern is the risk of \u201cserotonin syndrome,\u201d which is thought to result from hyperstimulation of brainstem 5-HT1A receptors and characterized by myoclonus, agitation, abdominal cramping, hyperpyrexia, hypertension, and potentially death. Serotonergic agonists taken in combination should be monitored closely for this reason. Considerations such as half-life, compliance, toxicity, and drug-drug interactions may guide the choice of a particular SSRI. Fluoxetine and its principal active metabolite, norfluoxetine, for example,"
    },
    {
        "id": "article-307_27",
        "title": "Dextromethorphan Toxicity -- Differential Diagnosis",
        "content": "Alcohol intoxication Amphetamine intoxication Anticholinergic poisoning Bipolar disorder Brain neoplasms Cocaine toxicity Diphenhydramine toxicity Delirium tremors Encephalitis Hyperthyroidism Hypoglycemia Hyponatremia Hypoxia Lysergic acid diethylamide (LSD) toxicity Malignant hyperthermia MDMA toxicity Neuroleptic malignant syndrome Serotonin syndrome Salicylate poisoning Toxic alcohol poisoning Trauma (self-induced or accidental) Meningitis/encephalitis Schizophrenia Sepsis SSRI toxicity [3] [4] [13]",
        "contents": "Dextromethorphan Toxicity -- Differential Diagnosis. Alcohol intoxication Amphetamine intoxication Anticholinergic poisoning Bipolar disorder Brain neoplasms Cocaine toxicity Diphenhydramine toxicity Delirium tremors Encephalitis Hyperthyroidism Hypoglycemia Hyponatremia Hypoxia Lysergic acid diethylamide (LSD) toxicity Malignant hyperthermia MDMA toxicity Neuroleptic malignant syndrome Serotonin syndrome Salicylate poisoning Toxic alcohol poisoning Trauma (self-induced or accidental) Meningitis/encephalitis Schizophrenia Sepsis SSRI toxicity [3] [4] [13]"
    },
    {
        "id": "Psichiatry_DSM-5_3392",
        "title": "Psichiatry_DSM-5",
        "content": "resulting from the use of other substances or medications, such as serotonin syndrome; parkinsonian hyperthermia syndrome following abrupt discontinuation of dopamine ag- thesia; hyperthermia associated with abuse of stimulants and hallucinogens; and atropine poisoning from anticholinergics. In rare instances, individuals with schizophrenia or a mood disorder may present with malignant catatonia, which may be indistinguishable from neuroleptic malignant syn- drome. Some investigators consider neuroleptic malignant syndrome to be a drug- induced form of malignant catatonia. 333.72 (624.02) Medication-Induced Acute Dystonia Abnormal and prolonged contraction of the muscles of the eyes (oculogyric crisis), head, neck (torticollis or retrocollis), limbs, or trunk developing within a few days of starting or raising the dosage of a medication (such as a neuroleptic) or after reducing the dosage of a medication used to treat extrapyramidal symptoms.",
        "contents": "Psichiatry_DSM-5. resulting from the use of other substances or medications, such as serotonin syndrome; parkinsonian hyperthermia syndrome following abrupt discontinuation of dopamine ag- thesia; hyperthermia associated with abuse of stimulants and hallucinogens; and atropine poisoning from anticholinergics. In rare instances, individuals with schizophrenia or a mood disorder may present with malignant catatonia, which may be indistinguishable from neuroleptic malignant syn- drome. Some investigators consider neuroleptic malignant syndrome to be a drug- induced form of malignant catatonia. 333.72 (624.02) Medication-Induced Acute Dystonia Abnormal and prolonged contraction of the muscles of the eyes (oculogyric crisis), head, neck (torticollis or retrocollis), limbs, or trunk developing within a few days of starting or raising the dosage of a medication (such as a neuroleptic) or after reducing the dosage of a medication used to treat extrapyramidal symptoms."
    },
    {
        "id": "InternalMed_Harrison_32104",
        "title": "InternalMed_Harrison",
        "content": "PART 18 Poisoning, Drug Overdose, and Envenomation 473e-6 in theophylline overdose. For poisons with central dopaminergic effects (methamphetamine, phencyclidine) manifested by psychotic behavior, a dopamine receptor antagonist, such as haloperidol, may be useful. In anticholinergic and cyanide poisoning, specific antidotal therapy may be necessary. The treatment of seizures secondary to cerebral ischemia or edema or to metabolic abnormalities should include correction of the underlying cause. Neuromuscular paralysis is indicated in refractory cases. Electroencephalographic monitoring and continuing treatment of seizures are necessary to prevent permanent neurologic damage. Serotonergic receptor overstimulation in serotonin syndrome may be treated with cyproheptadine. Other Measures Temperature extremes, metabolic abnormalities, hepatic and renal dysfunction, and secondary complications should be treated by standard therapies.",
        "contents": "InternalMed_Harrison. PART 18 Poisoning, Drug Overdose, and Envenomation 473e-6 in theophylline overdose. For poisons with central dopaminergic effects (methamphetamine, phencyclidine) manifested by psychotic behavior, a dopamine receptor antagonist, such as haloperidol, may be useful. In anticholinergic and cyanide poisoning, specific antidotal therapy may be necessary. The treatment of seizures secondary to cerebral ischemia or edema or to metabolic abnormalities should include correction of the underlying cause. Neuromuscular paralysis is indicated in refractory cases. Electroencephalographic monitoring and continuing treatment of seizures are necessary to prevent permanent neurologic damage. Serotonergic receptor overstimulation in serotonin syndrome may be treated with cyproheptadine. Other Measures Temperature extremes, metabolic abnormalities, hepatic and renal dysfunction, and secondary complications should be treated by standard therapies."
    },
    {
        "id": "article-30379_13",
        "title": "Selective Serotonin Reuptake Inhibitor Toxicity -- Treatment / Management",
        "content": "Nelson\u00a0et al. [24] established guidelines for out-of-hospital management of isolated SSRI overdose and recommended at-home observation of patients who were experiencing minor symptoms and had ingested less than 5 times their own prescribed dose or less than 5 times the initial adult dose in an SSRI-naive patient.\u00a0This should only be done\u00a0in close conjunction with a regional poison control center.",
        "contents": "Selective Serotonin Reuptake Inhibitor Toxicity -- Treatment / Management. Nelson\u00a0et al. [24] established guidelines for out-of-hospital management of isolated SSRI overdose and recommended at-home observation of patients who were experiencing minor symptoms and had ingested less than 5 times their own prescribed dose or less than 5 times the initial adult dose in an SSRI-naive patient.\u00a0This should only be done\u00a0in close conjunction with a regional poison control center."
    },
    {
        "id": "article-17465_2",
        "title": "Amitriptyline -- Indications",
        "content": "Amitriptyline\u00a0is FDA\u00a0approved medication to treat major depressive disorder (MDD) in adults. [1] The non-FDA-approved indications\u00a0include anxiety, post-traumatic stress disorder, insomnia, chronic pain (diabetic neuropathy, fibromyalgia), irritable bowel syndrome, interstitial cystitis\u00a0(bladder pain syndrome), migraine prophylaxis, postherpetic neuralgia, and\u00a0sialorrhea. [2] [3] [4] Amitriptyline has been used for post-COVID headaches. [5]",
        "contents": "Amitriptyline -- Indications. Amitriptyline\u00a0is FDA\u00a0approved medication to treat major depressive disorder (MDD) in adults. [1] The non-FDA-approved indications\u00a0include anxiety, post-traumatic stress disorder, insomnia, chronic pain (diabetic neuropathy, fibromyalgia), irritable bowel syndrome, interstitial cystitis\u00a0(bladder pain syndrome), migraine prophylaxis, postherpetic neuralgia, and\u00a0sialorrhea. [2] [3] [4] Amitriptyline has been used for post-COVID headaches. [5]"
    },
    {
        "id": "InternalMed_Harrison_8888",
        "title": "InternalMed_Harrison",
        "content": "damage of endothelium. Deep venous thrombosis is also observed with use of thalidomide, lenalidomide, or pomalidomide in combination with dexamethasone. Raynaud\u2019s phenomenon and impaired circulation may result if the M component forms cryoglobulins, and hyperviscosity syndromes may develop depending on the physical properties of the M component (most common with IgM, IgG3, and IgA paraproteins). Hyperviscosity is defined based on the relative viscosity of serum as compared with water. Normal relative serum viscosity is 1.8 (i.e., serum is normally almost twice as viscous as water). Symptoms of hyperviscosity occur at a level greater than 4 centipoise (cP), which is usually reached at paraprotein concentrations of ~40 g/L (4 g/dL) for IgM, 50 g/L (5 g/dL) for IgG3, and 70 g/L (7 g/dL) for IgA; however, depending on chemical and physical properties of the paraprotein molecule, it can occasionally be observed at lower levels.",
        "contents": "InternalMed_Harrison. damage of endothelium. Deep venous thrombosis is also observed with use of thalidomide, lenalidomide, or pomalidomide in combination with dexamethasone. Raynaud\u2019s phenomenon and impaired circulation may result if the M component forms cryoglobulins, and hyperviscosity syndromes may develop depending on the physical properties of the M component (most common with IgM, IgG3, and IgA paraproteins). Hyperviscosity is defined based on the relative viscosity of serum as compared with water. Normal relative serum viscosity is 1.8 (i.e., serum is normally almost twice as viscous as water). Symptoms of hyperviscosity occur at a level greater than 4 centipoise (cP), which is usually reached at paraprotein concentrations of ~40 g/L (4 g/dL) for IgM, 50 g/L (5 g/dL) for IgG3, and 70 g/L (7 g/dL) for IgA; however, depending on chemical and physical properties of the paraprotein molecule, it can occasionally be observed at lower levels."
    },
    {
        "id": "Psichiatry_DSM-5_3398",
        "title": "Psichiatry_DSM-5",
        "content": "Discontinuation symptoms may occur following treatment with tricyclic antidepressants (e.g., imipramine, amitriptyline, desipramine), serotonin reuptake inhibitors (e.g., \ufb02uox- etine, paroxetine, sertraline), and monoamine oxidase inhibitors (e.g., phenelzine, selegi- line, pargyline). The incidence of this syndrome depends on the dosage and half-life of the medication being taken, as well as the rate at which the medication is tapered. Short-acting medications that are stopped abruptly rather than tapered gradually may pose the great- est risk. The short-acting selective serotonin reuptake inhibitor (SSRI) paroxetine is the agent most commonly associated with discontinuation symptoms, but such symptoms oc- cur for all types of antidepressants.",
        "contents": "Psichiatry_DSM-5. Discontinuation symptoms may occur following treatment with tricyclic antidepressants (e.g., imipramine, amitriptyline, desipramine), serotonin reuptake inhibitors (e.g., \ufb02uox- etine, paroxetine, sertraline), and monoamine oxidase inhibitors (e.g., phenelzine, selegi- line, pargyline). The incidence of this syndrome depends on the dosage and half-life of the medication being taken, as well as the rate at which the medication is tapered. Short-acting medications that are stopped abruptly rather than tapered gradually may pose the great- est risk. The short-acting selective serotonin reuptake inhibitor (SSRI) paroxetine is the agent most commonly associated with discontinuation symptoms, but such symptoms oc- cur for all types of antidepressants."
    }
]